Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 8/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 4/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5486147 | 0.87 | MAPK1 (0.47) | LMNAGAATSPOSMN1; SMN2CYP1A2 | |
| SCHEMBL5493764 | 0.86 | MAPK1 (0.49) | LMNAGAATSPOSMN1; SMN2CYP1A2 | |
| SCHEMBL6625966 | 0.77 | MAPK10 (0.42) | POLBCYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL5493513 | 0.75 | GABRA5 (0.41) | MDM2TP53LMNAACHEPOLB | |
| SCHEMBL5484921 | 0.75 | CYP1A2 (0.50) | TP53LMNAGAASMN1; SMN2CYP1A2 | |
| SCHEMBL5484053 | 0.75 | CYP1A2 (0.50) | LMNAGAAACHESMN1; SMN2CYP1A2 | |
| SCHEMBL5492941 | 0.75 | CYP1A2 (0.47) | LMNAGAAACHESMN1; SMN2CYP1A2 | |
| SCHEMBL29942019 | 0.75 | CYP1A2 (0.62) | LMNAGAASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL5492316 | 0.75 | ALDH1A1 (0.53) | TP53LMNAGAASMN1; SMN2CYP1A2 | |
| SCHEMBL5490244 | 0.74 | CYP1A2 (0.46) | LMNAGAASMN1; SMN2TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | claimed |
| US-7250410-B2 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | VIA PHARMACEUTICALS, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | disclosed |
| EP-1392663-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098865-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | PDE7A, PDE3B, PDE3A | MDM2 4824/4885TP53 4880/4885LMNA 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.